ECDC publishes today the results of its first point prevalence survey (PPS) on healthcare-associated infections and antimicrobial use in European hospitals. Based on findings from this survey, ECDC estimates that on any given day, one in 18 patients in European hospitals has at least one healthcare-associated infection. The report also presents data on the most commonly reported infections, which microorganisms are most commonly reported as causing them, how often antimicrobial drugs are being used to treat these infections and data on infection control structure and processes in the hospitals. More than 1 000 hospitals in 30 European countries participated in this first Europe-wide PPS.

Healthcare-associated infections are those acquired by patients during their stay in a hospital or other healthcare setting. Although some of these infections can be treated easily, others may more seriously affect a patient’s health, increasing their stay in the hospital, requiring further surgical intervention or prolonged treatment with antimicrobials and causing considerable distress to these patients.

Through the ECDC PPS, a major step has been made towards increasing the skills for surveillance of healthcare-associated infections and antimicrobial use, and raising awareness of healthcare-associated infections among thousands of healthcare workers across Europe. The survey provides the most comprehensive database on healthcare-associated infections and antimicrobial use in European acute care hospitals to date, and based on these results ECDC has made recommendations that should be further developed and implemented across Europe.

Marc Sprenger, ECDC Director, said: "The survey confirms that healthcare-associated infections pose a major public health problem and a threat to European patients: ECDC estimates that on any given day, about 80 000 patients, i.e. one in 18 patients, in European hospitals have at least one healthcare-associated infection". Overall, this amounts to an estimated total of 3.2 million patients (95% confidence interval: from 1.9 to 5.2 million) each year.

He added: “Many of these infections could be prevented by sustained, multifaceted infection prevention and control programmes, including surveillance of healthcare-associated infections. Such programmes, as well as prudent use of antibiotics, will help all actors involved to protect the patients of European hospitals”.

Paola Testori Coggi, Director General of DG Health and Consumers, European Commission, said: "This survey represents an important milestone in monitoring healthcare-associated infections across Europe. Their prevalence is worrying and increased efforts are needed at local, national and European level to prevent such infections, for the safety of patients. Such efforts are also needed to fight against the development of antimicrobial resistance. The European Commission is actively monitoring the situation with the support of the European Centre for Disease Prevention and Control, and works in cooperation with the Member States to implement the 2009 Council Recommendation on Patient Safety.”

The prevalence of healthcare-associated infections was the highest among patients admitted to intensive care units (ICUs) in these hospitals, where 19.5% patients had at least one. The most common types of healthcare-associated infection in these ICUs were respiratory tract infections and bloodstream infections. Overall, of a total of 15 000 reported healthcare-associated infections, the most commonly reported types were respiratory tract infections (pneumonia, 19.4%; lower respiratory tract infections, 4.1%), surgical site infections (19.6%) and urinary tract infections (19.0%).

The survey also confirms that a large proportion of patients receive antimicrobial agents while being hospitalised. ECDC estimates that more than 400 000 patients, i.e. one in three patients, receive at least one antimicrobial agent on any given day in European hospitals. The following areas for improvement were identified: limiting the use of broad-spectrum antimicrobials, reducing the unnecessary prolongation of surgical prophylaxis, promoting earlier change from parenteral to oral administration of antimicrobials, and improving the documentation of the reason for the antimicrobial use in the patients’ charts.
Finally, "ECDC has provided individual results to the participating hospitals through the national PPS coordinators. In this way, these hospitals can interpret their own data, see how they are doing both at an individual and national level and identify areas where improvements can be made", Marc Sprenger mentioned.

ECDC will organise a second Europe-wide point prevalence survey in all Member States in 2016–2017 and will continue supporting the organisation, data collection, validation and analysis of national surveys during the period 2013–2015.

Other findings:
- About half (54.1%) of the healthcare-associated infections were reported with microbiological results on the day of the survey. Among these, the ten most commonly isolated microorganisms in HAIs were Escherichia coli (15.9%), Staphylococcus aureus (12.3%), Enterococcus species (9.6%), Pseudomonas aeruginosa (8.9%) Klebsiella species (8.7%), coagulase-negative staphylococci (7.5%), Candida species (6.1%), Clostridium difficile (5.4%), Enterobacter species (4.2%), Proteus species (3.8%) and Acinetobacter species (3.6%).
- Among all Staphylococcus aureus isolates with known results from antimicrobial susceptibility testing, 41.2% were reported as resistant to meticillin (i.e. were MRSA). Among all isolates of Enterococcus species with known results, 10.2% were reported as resistant to vancomycin. Among all isolates of Enterobacteriaceae with known results, 33.4% and 7.6% were reported as resistant to third-generation cephalosporins and to carbapenems, respectively.

Background information
- **Point prevalence survey**: A prevalence survey is a count of the number of patients with a particular condition/treatment (in this case either a healthcare-associated infection or an antimicrobial agent) at a particular time (in this case a day), as a proportion of the total number of patients who are hospitalised at that particular time. A point prevalence survey only counts the condition/treatment if present at the time (on the day) of the survey, but does not count it if present at other times during the patient stay in the hospital.
- **Development of the survey**: 30 countries used the same point prevalence survey standardised protocol. An estimated 2 800 healthcare workers from 1 200 hospitals across Europe were trained by national coordinating staff to implement the standardised methodology. Data from a total of 273 753 patients in 1 149 hospitals were submitted to ECDC. Of these, 231 459 patients from 947 hospitals were included in the final European sample for analysis.

Relevant links
- Point prevalence survey of healthcare-associated infections and antimicrobial use in European hospitals 2011–2012
- ECDC Antimicrobial Resistance and Healthcare-associated Infections programme
- Protocol: Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals
- European Antimicrobial Resistance Surveillance Network (EARS-Net)
- European Surveillance of Antimicrobial Consumption Network (ESAC-Net)
- ECDC HAI-Net PPS interactive database
- European Antibiotic Awareness Day
- Systematic review and evidence-based guidance on perioperative antibiotic prophylaxis
- Council Recommendation of 9 June 2009 on patient safety, including the prevention and control of healthcare associated infections (2009/C 151/01)

ECDC press office
Tel: +46 (0)8 58 60 16 78
Email: press@ecdc.europa.eu

Notes
- One in 18 patients is the average figure for Europe. This figure may vary depending on the country.
- In this press release, European hospitals refer to European acute care hospitals, including primary, secondary, tertiary and specialised hospitals.

The European Centre for Disease Prevention and Control (ECDC) is an EU agency tasked with identifying assessing and communicating threats to human health posed by infectious diseases. It supports the work of public health authorities in the EU and EEA/EEA Member States.